Antibody response after measles immunization

Churdchoo Ariyasriwatana1, Siripen Kalayanarooj, Sirima Pattamadilok

  • 1Department of Social Pediatrics, Queen Sirikit National Institute of Child Health, Bangkok 10400, Thailand.

Abstract

Insights

Measles vaccination at 9 months shows a 68.75% seroconversion rate, but antibody levels wane by 18 months. A booster dose at 15 months is suggested to improve measles protection in children.

Area of Science:

  • Immunology
  • Pediatrics
  • Public Health

Background:

  • Measles remains a significant public health concern in Thailand, despite widespread vaccination since 1984.
  • Vaccine failure is a suspected contributor to the persistent high incidence of measles.

Purpose of the Study:

  • To determine the seroconversion rate in infants vaccinated against measles at 9 months of age.
  • To assess measles antibody levels in children at 18 months and 4 years old following vaccination.

Main Methods:

  • Infants and children attending routine immunization clinics were enrolled.
  • Group A (9-month-olds) had blood drawn before and 3 months after measles vaccination.
  • Groups B (18-month-olds) and C (4-year-olds) had a single blood sample drawn; measles antibody levels were measured using micro-neutralization.

Main Results:

  • Only 6.5% of 9-month-old infants had detectable measles antibody before vaccination.
  • Seroconversion rates were 68.75% at 3 months post-vaccination (9-month-olds) and 53.3% at 9 months post-vaccination (18-month-olds).
  • Geometric Mean Titer (GMT) increased significantly with age, from 1:2.5 (9 months) to 1:73.8 (4 years), but showed a decline by 18 months (1:8.2).

Conclusions:

  • While measles vaccination at 9 months yields a nearly 70% seroconversion rate, antibody levels decrease significantly by 18 months.
  • The observed waning antibody levels suggest vaccine failure may contribute to measles incidence.
  • A measles booster dose at 15 months is recommended to enhance antibody levels before 18 months, improving protection.

Related Concept Videos

Immunological Memory01:23

Immunological Memory

Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Cross-reactivity00:42

Cross-reactivity

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccinations01:51

Vaccinations

Overview
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview